About the project

 

V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 9 partner organisations.
The 14 Early Stage Researchers (ESRs) will be a part of  the unique international PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to  ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.

News

  • New effective way to inhibit lymphatic malformations

    Lymphatic malformation is a debilitating and often incurable disease. Taija Mäkinen’s research group has in an international collaboration studied cellular mechanisms leading to abnormal vessel growth and identified a combination therapy that may allow effective treatment of these malformations. Lymphatic malformations are often congenital vascular anomalies that are characterised by abnormal vessel growth. These malformations

  • Theranostic Advances in Vascular Malformations

    V Dekeuleneer, E Seront, A Van Damme, LM Boon, M Vikkula Until a few years ago, treatment options of vascular malformations were limited to sclerotherapy and/or surgery. Since, it has been demonstrated that the majority of vascular malformations are caused by inherited or somatic mutations in various genes. These discoveries paved the way for the

  • Finnadvance is funded for further research

    Finnadvance’s got funded for blood vessel-on-a-chip which could be used to treat rare vascular diseases! Organ- or body-on-chips both speed up the process and improve the safety and patient outcomes. Futuristic, but this can be a reality in 3-5 years! Official press release Finnadvance completes 550k€ seed round led by Voima Ventures and Finnish biotech

V.A. Cure
@VACure1



Our student @Tala_AlTabosh at @BaillySabine lab is establishing a cellular model for #HHT by isolating endothelial colony-forming cells from the blood of HHT patients. With this minimally invasive procedure, patient-derived endothelial cells have become more accessible! #msca https://t.co/PbN1AAxYP5

View on Twitter

VACure1 photo

0

4

Follow us on Facebook

Project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 814316